Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus (ATTAIN2)

Cumberland Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Bacterial Pneumonia

Treatments: Drug: Vancomycin; Drug: Telavancin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00124020

0019

Details and patient eligibility

About

Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.

Enrollment: 771 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic care facility or acquired within 7 days after being discharged from a hospitalization of greater than or equal to 3 days duration.

Exclusion criteria

• Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy for Gram-positive pneumonia immediately prior to randomization.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

771 participants in 2 patient groups

Telavancin

Experimental group

Treatment:

Drug: Telavancin

Vancomycin

Active Comparator group

Treatment:

Drug: Vancomycin